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Follicular lymphoma (FL) is the most common indolent B-cell lymphoma in 
western countries. Overall, 70% of the patients achieve complete remission 
after first treatment.1 However, it is characterized by a pattern of relapsing and 
remitting disease. The outcome of patients with FL has clearly improved,2 but 
heterogeneity in patients’ survival still remains, making the quest for reliable 
prognostic factors a relevant issue.  
Response assessment of patients with FL can be performed with CT scan and 
[18F]fluorodeoxyglucose – Positron Emission Tomography (FDG-PET) scan. 
FDG-PET has been confirmed to have the highest accuracy and was shown to 
be independent of CT scan and to be a stronger predictor of outcome.3 
Recently, PET has been acknowledged as a recommended procedure for FL 
staging and response assessment.4 Moreover, the assessment of MRD by 
qualitative and quantitative polymerase chain reaction (PCR) for Bcl2/IgH has 
been evaluated as a prognostic tool in FL.5 Nevertheless the impact of both end 
of treatment (EOT) PET and MRD in prognostic assessment remains to be 
determined. 
The aim of the present study was to analyze the prognostic role of combined 
PET and BCL2/IGH analysis, performed at the EOT, in a subset study of the 
phase III trial FOLL05 (NCT00774826), in which patients with FL were 
randomized to R-CVP (rituximab plus cyclophosphamide, vincristine and 
prednisone), R-CHOP (rituximab plus cyclophosphamide, doxorubicin, 
vincristine and prednisone) or R-FM (rituximab plus fludarabine and 
mitoxantrone).6 This study was conducted in compliance with the Declaration of 
Helsinki, was approved by the appropriate research ethics committee, and 
required each patient to provide written informed consent. 
In order to be considered for the current study, patients were required to have 
been enrolled in the FOLL05 trial that included previously untreated high tumor 
burden Ann Arbor stage II to IV FL grade 1,2,3a.6  Of note, the FOLL05 study 
included MRD evaluation at the EOT among planned study procedures.5 Also, 
for the purpose of this study patients should also have available data on EOT 
PET, performed up to three months after the last dose of induction rituximab 
(+/- chemotherapy) and assessed for the BCL2/IGH at diagnosis and at the 
EOT within 2 months from last dose. Data on clinical presentation, treatment, 
response and follow-up were retrieved from the existing and published dataset 
of the randomized protocol. 
PET was centrally reviewed by three independent nuclear medicine physicians 
applying the Deauville scale. Positive scans (PET+) were defined by residual 
FDG uptake ≥ score 4 (i.e. uptake moderately > liver uptake). Final result was 
assigned by agreement between at least two of three reviewers. 
Regarding MRD analysis, patients underwent bone marrow (BM) aspirate for 
qualitative and quantitative assessment of the BCL2/IGH fusion gene. DNAs 
from the patients were assessed for the BCL2/IGH at diagnosis, and if positive, 
at the EOT. All qualitative molecular analyses were centralized at the molecular 
laboratory of the Division of Hematology of the Pisa University, Italy. DNA was 
extracted from BM mononuclear cells by the Wizard Genomic DNA Purification 
Kit (Promega). To amplify BCL2/IGH rearrangement, nested qualitative PCR 
reactions were performed.7 The sensitivity of the qualitative PCR assays was 
confirmed by testing serial dilutions of DNA derived from the BCL2/IGH-positive 
DOHH-2 cell line, achieving a limiting dilution of 1:10-5. A second reaction for 
mcr breakpoint was also performed as already reported.8 
The primary endpoint was progression-free survival (PFS), that was calculated 
as the time from the date of treatment start until the date of lymphoma 
progression, relapse, death from any cause or last follow-up visit. Standard 
descriptive analyses were carried out. For a crude association analysis, 
categorical data were analyzed using the chi-square or Fisher’s exact test (two-
sided). Cohen’s kappa statistic was used to verify agreement between PET and 
MRD results. The level of agreement was defined by Koch Landis scale. 
Survival curves were estimated using the Kaplan–Meier method and compared 
using the log-rank test. Univariate Cox regression analyses were conducted to 
verify the prognostic role of final PET and MRD regarding PFS. Two-tailed P 
values <0.05 were considered statistically significant. Statistical analysis was 
carried out with SPSS software (ver 18.0,Chicago, IL). 
A total of 41 patients had available data on both PET and BCL2/IGH at the 
EOT. The median age was 54 years (39-71). Baseline characteristics of the 
study population did not differ from that of the FOLL05 study (Table 1). The 
distribution of cases according to EOT PET and MRD is shown in Table 2. 
PET/MRD concordance was 76%, with Kappa=0.249, suggesting that PET and 
MRD when done at the end of induction therapy are not strongly correlated.  
With a median follow up of 53 months (from 13 to 77 months) 5 year PFS was 
62% (95% CI 45 to 75). By univariate analysis, EOT PET+ was associated to a 
poorer PFS (HR 3.61, 95%CI 1.15-11.4, P=.028), while the EOT positive 
molecular status had a trend towards a shorter PFS (HR 2.54, 95%CI 0.96-
6.72, P=.060) (Figure 1). 
In a stratified analysis combining the information of PET and MRD, the 3-y-PFS 
were 78%, 50% and 27% in PET/MRD -/-, PET/MRD -/+ and PET+ groups, 
respectively (p=0.015 for all groups, and p=0.067 between PET/MRD -/- and 
PET/MRD -/+). We also stratified the patients in 2 groups (PET-/MRD- vs PET+ 
or MRD+), and the achievement of both PET and MRD negativity was 
associated to a better outcome (HR 3.42, 95%CI 1.31-8.95, P=.012), with 5-yr 
PFS of 75% (95% CI 54 to 87%) and 35% (95% CI 11 to 60%) for PET/MDR -/- 
and PET+, respectively (Figure 2). 
To the best of our knowledge, this is the first report combining the information of 
PET and MRD at the end of the induction treatment in FL patients. Although this 
is a small subset of a large trial, the present results can provide some insights 
for future prospective trials. 
The results showed that PET and MRD are not strongly correlated with each 
other and they can be used as complementary techniques at the end of therapy. 
PET is more accurate for nodal disease, but has important limitations in bone 
marrow analysis because BM involvement in FL is usually diffuse and with low 
volume. In contrast, MRD analysis describes disease at BM level and it can 
reach a very high sensitivity, up to 10-5.  
The small study sample represents a major limitation of this study and is due to 
its retrospective nature and to the established inclusion criteria; MRD analysis 
was a planned procedure in the FOLL05 trial, but a molecular marker was only 
available in about 60% of patients.5 When FOLL05 was designed, PET was not 
acknowledged as a recommended procedure for staging and response 
assessment in FL, and so it was not included among the planned study 
procedures; however, it was performed at physician discretion in substantial 
proportion of cases.9 In addition while FDG avidity is almost universally present 
in FL, with current PCR techniques using both major and minor breakpoint sites 
for BCL2/IGH MRD analysis, as done in the present study, only around 50-60% 
of patients can be studied. This rate can be improved with better methods and 
technologies (VDJ region analysis or rarer breakpoint regions of BCL2/IGH 
chromosomal translocation). Although conducted on a small set of patients the 
strength of this study is the use of blinded central review of FDG-PET scans, 
the use of Deauville criteria and of dedicated central lab for MRD analysis.  
In the last years, the concept that tumor cells release circulating free DNA 
(cfDNA) into the blood by cells undergoing apoptosis or necrosis enabled the 
use of whole exome sequencing (“next generation sequencing technologies” – 
NGS) to detect observed tumor mutations in blood.10 Recently this technology 
was validated in DLBCL and allowed the same group to launch a prospective 
study in the aim of serial sequencing cfDNA during DLBCL treatment and 
follow-up.11 This new tool named “liquid biopsy” and the use of peripheral blood 
might further improve MRD studies in FL. 
In conclusion, although conducted on a small series of patients, this study 
shows that combining both EOT FDG-PET and MRD analysis in patients with 
FL may improve our ability to predict the risk of progression and provides the 
rationale to design response adapted trials in FL to tailor post induction therapy 
to the real risk of relapse. Based on these results, the Fondazione Italiana 
Linfomi (FIL) planned the FOLL12 trial to investigate the efficacy of a response-
adapted strategy, using EOT PET and MRD study in patients with FL 
(ClinicalTrials.gov Identifier: NCT02063685). In the study all patients receive 6 
cycles of R-CHOP or R-bendamustine followed by 2 additional doses of 
rituximab. All responsive patients in the standard arm are treated with standard 
2 year maintenance with rituximab. Responding patients in the experimental 
arm receive post-induction therapy based on PET and MRD results: PET- 
patients do not receive maintenance but are treated with pre-emptive treatment 
with rituximab if MRD+; PET+ positive patients receive as consolidation a (90)Y 
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Table 1.  Comparison  of baseline characteristics of study population and 
FOLL05 patients 






       p 
n % n % 
Age > 60 11 27  156 34     0.39 
Male sex 19 46  245 53     0.42 
Ann Arbor stage III-IV 38 93  423 91     1.0 
Bulky disease (> 6 cm) 16 39 118 25     0.07 
BM involvement 23 56  251 54     0.47 

































Table 2.  Distribution of patients according to PET response and MRD at the 
end of treatment 
 PET negative PET positive 
MRD negative 28 (68%) 2 (5%) 





Figure 1 A: PFS by PET; Figure 1 B: PFS by MRD 
Figure 2: PFS according to combination of PET and MRD results. 
 


